Malorni et al. indicated that the expression of both E2F1 and E2F2 could cause loss of Rb and predict the sensitivity of cell lines to palbociclib in luminal breast cancer (Malorni et al., 2016). The gene discussed is RB1; the disease is breast carcinoma.